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Abstract 
 
Alveolar echinococcosis (AE) is a zoonosis caused by the ingestion of eggs of the 
tapeworm Echinococcus multilocularis, causing a severe infection most often 
localized in the liver. Its behavior is similar to that of a malignant tumor as it invades 
surrounding tissues and can metastasize to distant organs. If left untreated, the 
mortality of AE can be as high as 90% after 10 years. In the immunosuppressed host, 
a higher incidence of AE has been reported. Additionally, AE seems to have a faster 
evolution, with more severe manifestations. However, there are very few data on the 
epidemiology and clinical manifestations of AE specifically in solid-organ transplant 
(SOT) recipients. 
In this multicentric case series, we retrospectively collected de novo cases of AE in 
SOT recipients by searching the STCS database in Switzerland and the FrancEchino 
registry in France  for cases from 01/2008 to 08/2018.   We  collected data about   the 
clinical presentation, diagnosis, treatment and outcome at each center using a 
standardized collection form. 
A total of 7 patients were identified (kidney=5, heart=1, lung=1), 5 in France and 
2 in Switzerland. Six patients presented with liver AE and one with lung AE. AE was  
asymptomatic at diagnosis in 4 patients and presented with abdominal  pain in 2 of 
them. One had undocumented symptoms. The median time between transplantation 
and diagnosis was 66 months (ranging from 12 to 240). Two patients had no liver 
lesions 26 and 43 months prior to diagnosis, respectively. Diagnosis was done by 
serology in all cases (Western-blot was positive in all 7 cases, Em2+ was positive in 
1/3, hydatic fluid antigen ELISA in 4/4 and indirect hemagglutination   in 3/3). 
Imaging was atypical in 2 cases, with a pseudo-tumoral appearance in one case. 
Biopsies confirmed AE in 3 cases but led to an erroneous diagnosis in one case. Four 
of the 7 patients were operated (all incomplete resections) and 2 died following the 
operation. Albendazole was started in all surviving patients and was well tolerated by 
all patients (tolerance undocumented in one case). AE remained stable in 3 of the 5 
cases and progressed in 1 case. The evolution is undocumented in one case. One 
patient died of cause unrelated to AE. 
The incidence of AE seems to be higher and its evolution faster in SOT recipients 
than in the general population. Our data also suggest that diagnosis of AE in this 
population is more challenging, with atypical imaging and sometimes misleading 
biopsies. In this series, post-operative mortality was  high, perhaps suggesting that  a 
more conservative approach is needed in this immunocompromised population. 
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Alveolar echinococcosis 
 
Epidemiology 
AE is a parasitic infection found in the northern hemisphere and is endemic in Central 
Europe, Northern America, North Asia and Eastern Europe. In Europe, estimates for 
the annual incidence per 100’000 individuals vary between 0.03 [1] and 0.26 [2]. 
Annual incidence per 100’000 persons has high as 7-98 has however been recorded 
in St-Lawrence island [3], mostly due to a high parasite density and the proximity of 
its inhabitants to dogs and foxes. AE seems to be spreading to other countries and its 
incidence also seems to be increasing, but it is not clear how progresses in diagnostic 
tools is responsible for this [4]. 
Studies assessing the epidemiology of AE by screening serology studies have 
estimated the prevalence in humans to be about 0.2% in [5], 0.1% in [6] and 0.01% 
in [7]. Interestingly, most patients that had positive ELISA by screening did not 
develop an active AE and had normal radiology or images compatible with so- called 
“abortive” lesions. This suggests a low susceptibility of human beings to E. 
multilocularis infection. It has been estimated that only one person in ten exposed  to 
E. multilocularis will develop AE [5]. The disease seems to develop in hosts with a 
predominant Th2 response, with a high level of IgE and IgG production [8, 9]. 
Abortive lesions are most often found in hosts with predominant Th1 response [9]. 
Cytokines profile also seems to be different: levels of IL-10 are lower in patients with 
abortive lesions than in patients with progressive lesions [10]. 13% of the cases of 
AE in [11] are found in family clusters, bringing further evidence to a possible genetic 
susceptibility [9]. 
Prevalence of AE has also been measured in its intermediate and definitive hosts. 
The prevalence of AE in foxes may highly vary at a regional level, with local preva- 
lence based on necropsy ranging from 1% to 75% in some parts of Germany [3]. 
Moreover, the parasite population also increases with the fox population, and as 
suggested by Schweiger et al [2] may cause a higher incidence of AE in humans. A 
4-fold increase of fox population was indeed recorded during the late 80s and early 
90s and was followed by a 3-fold increase of the incidence of AE in humans for the 
2001-5 period in Switzerland. The ten years interval roughly corresponds to the es- 
timated latency time of AE. Additionally, E. multilocularis was also found in urban 
environment, in Zu¨rich [12], raising the question of the risk of transmission outside 
of rural areas. 
Most patients are diagnosed in their fifties, with an identical prevalence in men 
and women. Several risk factors for AE have clearly been identified: being a farmer 
(OR 4.7) or living in rural areas (OR 7), gardening, in particular growing leafy 
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vegetables or roots (OR 2.5), owning a dog (OR 4.2, 18.0 if it is a hunting dog), to 
cite a few. A complete risk score, with eleven independent items has been developed 
in [13]. The most important and robust risk factor remains to live in an endemic area 
(RR 80) [14]. 
 
Cycle 
Humans are an accidental host in the sylvatic infection cycle of E. multilocularis. The 
cycle is summarized in Figure 1. The definitive hosts are wild carnivores, such as red 
fox in Switzerland, although domesticated animals such as dogs and cats can also be 
infected. The adult worm stays in the small intestine of its definitive host and releases 
gravid proglottids (the mature reproductive part of the worm) containing eggs in the 
feces of its host. 
The egg is composed of an oncosphere (the first stage of the larva) surrounded by 
an embryophore and a vitelline layer, which is lost when the egg is released. The em- 
bryophore makes Echinococcus eggs particularly resistant: they can survive months 
once deposited in the environment and resist to temperature below 0◦C and to some 
commercially available disinfectants. However, desiccation is quickly fatal, killing 
the eggs in a matter of days. Likewise, the eggs are sensitive to high temperatures and 
will rapidly die if exposed to temperatures in the range of 60-80◦C[15]. 
Small rodents (typically, the common vole) act as intermediate hosts. When  they 
ingest eggs, the action of the digestive enzymes helps release the oncosphere from its 
protective membranes. The oncosphere then infiltrates the bowel walls and enters 
either the lymphatic or the blood circulation.  From  there,  it first reaches   the liver, 
although the brain, the kidneys, the lungs or other organs may also be primarily 
infected. Upon reaching the infection site, the oncosphere transforms into the 
secondary larval stage, the metacestode. Metacestodes form vesicles filled by 
protoscolices and a viscous liquid. The wall of the vesicles is composed of an outer 
acellular layer and a layer of germinal totipotent cells. Ultimately, when the rodent is 
consumed by a predator, the protoscolices are freed and infect the predator’s bowel, 
ending the cycle. 
Sylvatic cycle actually accounts for most of human infections, although it is still 
possible to be contaminated by domestic animals [17]. Indeed, owning a dog or cat 
may increase the risk of contamination [18]. Unlike rodents, humans are a dead-end 
in the parasitic cycle as very few protoscolices are produced by the metacestodes. 
In humans, alveolar echinococcosis lesions can attain sizes of up to 20cm, com- 
posed of multiple vesicles. The center of the lesion is usually necrotic, due to a 
reduced access to nutrients. A key difference between alveolar echinococcosis and 
the hydatic disease lies in the growth of the lesion. While hydatic cysts remain well 
delimited, alveolar echinococcosis exhibits an infiltrative growth and the possibility 
of distant metastases. Germinal cells or small vesicles shed in the blood stream or 
lymphatic circulation are thought to be the cause of the metastases [15]. 
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Figure 1: Cycle of E. multilocularis, reproduced from [16] 
 
Alveolar echinococcosis in humans 
Clinically, AE shares some characteristics with malignant tumors: the parasitic  mass 
grows without symptoms for a latency period of about 10-15 years.   The   first 
symptoms are often non-specific and at the time of diagnosis, AE may have 
metastasized to distant organs. The only curative treatment is a complete resection of 
the lesion, which may not be possible if the disease has excessively spread. In case 
of partial resection, a lifelong treatment of parasitostatic drugs will be needed, 
typically albendazole. AE initially had a poor prognosis, with 70% and 90% death 
rate at 5 and 10 years, respectively [3]. Introduction of benzimidazole drastically 
improved the situation, with a ten-year survival rate of about 90% as of 2005 and a 
lifespan shortened by 3 years [19]. 
 
Clinical manifestations 
After the infection, AE remains asymptomatic for an estimated period of 10-15 years 
[15]. Most patients are symptomatic at diagnosis: 73% in [20] and 71% in [11]. The 
other cases are either diagnosed during mass screening or are incidental findings 
discovered during imaging for another disease.  The usual presenting symptoms   are 
nonspecific but are suggestive of gastrointestinal or hepatic disease: abdominal pain, 
jaundice sometimes with fever and anemia [15]. AE can also present with unspecific 
symptoms such as an isolated asthenia, a chronic cough or an allergic angioedema 
[11], reflecting the invasive nature of AE. Indeed, for up to one third of the patients 
[11, 15], the disease already affects organs adjacent to the liver and for 
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10% of patients, AE has already metastasized at diagnosis [15]. The most frequent 
locations for metastases are the brain, the lungs and the spleen. Infiltrative growth 
can damage the diaphragm, the kidney, the adrenal glands, the lungs or the pleura. 
Extra-hepatic lesions without liver involvement is rare, accounting for about 4% of 
cases [11]. In most cases, the disease starts in the right lobe of the liver [3]. 
 
Diagnostic tools 
According to the WHO-Informal Working Group on Echinococcosis [3], a confirmed 
AE case is defined as a patient with a clinical and epidemiological history, imaging 
and serology compatible with AE, plus a confirmation by histopathology or PCR. 
This classification reflects the different diagnostic tools available to the clinician: 
anamnestic and epidemiological findings, the morphology of the lesions, immunodi- 
agnostic tools and to a lesser extent, pathology and molecular tools [3]. A positive 
serology is not sufficient to establish a diagnosis of AE, since antibodies can be 
detected in patients whose immune system cleared the infection. 
Imaging techniques are a cornerstone for the diagnosis of AE and for the PNM 
staging of the disease [21]. Unlike cancer, neither the PNM stage nor the presence of 
metastases seem to correlate with the prognosis [11]. This is best explained by the 
efficacy of albendazole to slow AE. US is the most available imaging modality, useful 
in the screening and follow-up, while Doppler is useful to study a potential invasion 
of the surrounding vessels [22]. It is however not as sensitive as CT or MRI to detect 
small lesions, calcifications, and to evaluate the extension of the lesions. However, 
contrast US using micro-bubbles seems to be promising to assess the activity of the 
disease [23]. CT is more sensitive than US, especially at assessing the size, extension 
and number of lesions and at detecting the almost pathognomonic calcifications 
pattern in the liver [3, 22, 23]. MRI is the best modality to study the soft tissue 
structure of the lesions (necrotic center, fibrous outer layer, parasitic vesicles, etc, ...) 
[23]. The pathognomonic “honeycomb” pattern, due to the multiple small vesicles, 
can sometimes be observed with MRI [22, 23]. Finally, MRI seems to be superior  to 
CT to assess the morphology of the invasion of the surrounding tissues, making  it 
particularly interesting for pre-operative evaluation [22]. PET-CT is also useful, 
particularly when checking for the presence of metastases and in the follow-up of the 
disease [24], but should not be used as an initial diagnostic tool as it lacks specificity 
[23]. 
Immunodiagnosis is another cornerstone technique at the disposal of clinicians 
to diagnose AE. Several tools have been developed over time and are summarized  in 
Table 1. One of the issue with AE serologies is their important cross-reactivity with 
E. granulosus, other parasitic disease and even cancer [25, 26]. Some of those 
serologies use crude antigens, usually offering a good sensitivity, some others use 
purified or recombinant antigens, improving the specificity at the cost of a lower 
sensitivity. Finally, whole larval antigens are also used in Western blots, offering good 
results. Indirect hemagglutination assay (IHA) uses E. granulosus antigens, but can 
also be used in AE. Em2 and Em2+ (Em2+ is a serology that associates purified Em2 
antigen and recombinant II/3-10 protein [27]), Em18 and Em4 are actually all 
degradation products of a larger protein, Em10 [28]. Also, some of those serologies 
have proven to be not only useful in the diagnosis, but also in the  follow- 
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Serology Sensitivity Specificity Remarks 
IHA [25] 74-94% ND Uses crude antigens. 
EgHF [27] 97% 61% Crude antigen ELISA based on hydatic fluid. 
Em2+ [27] 97.1% 99% Two-antigens ELISA: purified Em2 and recombi- 
   nant II/3-10. Used for follow-up : fall in antibody 
   titers may indicate a complete resection [29]. 
Em2 [27] 89% 100%  
Em18 [26] 97% 74% Not commercially available. Titers reflect PNM 
   staging. May be used for follow-up [29]. 
Western Blot [25] 96% 88-100% Several patterns are specific for AE and can be 
   used to differentiate the forms of echinococcosis 
 
Table 1: AE serologies 
 
up of the disease, in conjunction with imaging techniques. This is typically the case 
for Em18 and Em2+ [29]. 
Finally, biopsies can also be helpful for the diagnosis of AE, particularly when 
both serologies and imaging have unclear results. However, diagnosis puncture are 
best avoided as they carry the risk of parasitic mass dissemination [15]. Histopathol- 
ogy may highlight the periparasitic granuloma and the parasitic vacuoles, while real- 
time PCR may be used to assess the viability of the parasites and PCR detect the 
presence of specific nucleic acids [15]. 
 
Treatment 
Treatment of AE follows the same principles as the treatment of cancer: complete 
resection should be attempted whenever possible, as it is curative. When the lesion if 
inoperable, a lifelong chemotherapy is indicated. 
PNM staging is a good help in choosing which treatment should be used. P1N0M0 
or P2N0M0 stages should undergo surgery, as there is good chances of a complete 
resection [30], it is however possible for only about 30% of patients [31]. Despite a 
complete resection, those patients should still follow 2 years of benzimidazole treat- 
ment due to the risk of having remaining viable parasitic tissue after the surgery.   For 
inoperable patients, a lifelong treatment of benzimidazoles is indicated. Partial 
resection of the parasitic mass has not shown any benefits and should be avoided [30]. 
However, palliative surgery or percutaneous interventions may be necessary due to 
secondary manifestations of AE: liver abscess, bile duct obstruction, etc, ... Liver 
transplantation may also be indicated in some specific cases, when resection is not 
possible or in case of hepatic failure. However, absence of any extra-hepatic le- sion 
is mandatory before considering liver transplantation, due to the risk of relapse in 
patients with an immunosuppressive treatment [9, 30, 32]. 
Currently, the chemotherapy of choice for AE is albendazole, with the usual posology 
of 400mg twice daily with a fat-rich meal. An alternative  is  another  molecule of the 
same class, mebendazole, taken three times daily and usually given when albendazole is 
not tolerated. Benzimidazoles may have serious hepatic and hematologic (neutropenia) 
adverse effects and may also cause alopecia [3]. Liver function and haemogram should 
be performed to monitor toxicity every two  weeks      at the beginning of the treatment, 
with the possibility of making the controls less frequent when the treatment is well 
tolerated [3, 30]. However, benzimidazoles are 
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only parasitostatic, justifying the lifelong treatment [33]. Despite this, abortive le- 
sions in previously inoperable patients treated by chemotherapy were reported [24]. 
Such patients would benefit from an interruption of the treatment, the difficulty being 
to assess the viability of the parasitic lesions. Standard imaging techniques are useless 
for this purpose [24], although certain MRI patterns have  been shown  to correlate 
with glucose uptake in PET-CT [34]. Serologies, in particular Em2+ and Em18 [29] 
and PET-CT with delayed acquisition [24, 35] have been shown to be useful as 
surrogate markers, particularly when used together and can be used to safely interrupt 
benzimidazoles treatment in some patients [24, 36]. 
Follow-up should include monitoring of the benzimidazole concentration in the blood, 
at least initially and every time the posology is changed [30]. Imaging should also be 
conducted regularly to ensure regression of the lesion. US may be done frequently while 
and MRI/CT is advised every 2-3 years [30]. 
 
Alveolar echinococcosis in immunocompromised patients 
Illustrating the importance of the immune system to control and eradicate AE, up to 
one fourth of the patients currently diagnosed with AE were immunocompromised 
[11]. Moreover, clinical manifestations, diagnosis and even radiologic manifestations 
have been shown to be modified in SOT recipients [32, 37, 38, 39, 40]. AE seems to 
develop faster, have a higher incidence, to sometimes have atypical imaging mim- 
icking cancer [32, 40] or with abscess-like appearance [32]. Serologies also seem to 
be less reliable for those patients. AE is more often a fortuitous discovery, some- times 
even discovered while hepatic surgery is performed [32, 37, 40]. Cases of AE were 
also reported in AIDS patients [41, 42], also showing a fast development of the lesions 
and falsely negative serologies. 
Conventional treatment with surgery and benzimidazole has been shown to work 
well for those patients, although albendazole was found to have more frequent side 
effects in immunosuppressed patients [32]. This was however not the case in two 
others studies in liver transplant patients [43, 44], despite the fear of interaction 
between albendazole and immunosuppressive drugs. 
To date, no study has  been  done  specifically  on  AE  in  SOT  recipients.  The only 
available data are case reports and studies of broader scope on AE in immuno- 
compromised patients. With this work, we aimed to determine the clinical mani- 
festations, the epidemiology and the specificity of the management of AE in SOT 
recipients.  As demonstrated in previous studies and case reports [32, 37, 38, 39, 40],  we 
expect to find a higher incidence as well as a faster evolution of AE in SOT recip- ients. 
We also expect to find the same diagnosis challenges as reported in previous papers: less 
reliable serologies and less typical imaging. Studies have had  contra- dicting results about 
albendazole tolerance in SOT recipients,  making  hypothesis  about this particular point 
is thus difficult. 
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Methods 
 
Study design 
This is a multicentric retrospective case series grouping cases of AE in France and 
Switzerland. To identify patients, we searched the STCS (Swiss Transplant  Co-  hort 
Study) database with keywords “ecchino”, “echino”, ”bandwurm”, “zoonose”, 
“parasite infection”, “echinococcus” and “other parasitic infections”. In France, the 
search was performed on the FrancEchino registry, looking for patients with the 
keywords “graft” and “transplant”. Only solid-organ transplant recipients were se- 
lected: patients that underwent bone marrow transplantation were excluded. We  also 
excluded patients that had liver transplantation in the context of AE. Patients were 
only included if the diagnosis of AE was made between start of 2008 (creation of the 
STCS, to have reliable data to estimate the incidence) and 08/2018 (end of  the data 
collection period). 
Information about cases was then retrieved from the patients file by mean of a 
standardized form. In Switzerland, a few cases with cystic echinococcosis had to be 
filtered out at this point as they had been selected by the echinococcosis keyword. 
The form includes information about the transplantation, the immunosuppressive 
drugs and if present, the last serologies and imaging that showed the absence of  AE. 
The clinical presentation, the results of the radiologic examinations and of the 
laboratory works, the treatment and the outcome of AE were also documented. 
 
The STCS cohort and the FrancEchino registry 
The FrancEchino network aims to group all AE cases in France  in a national registry,  the 
FrancEchino registry [45]. The registry is managed by the National Reference Center for 
Alveolar Echinococcosis, in Besanc¸on.  Cases have been registered retro- spectively 
for the 1982 to 1996 period and prospectively since then. The registry included 691 
patients as of 2017.  Since there is no legal obligation to declare AE   cases, the 
FrancEchino network detects new cases by monitoring the prescription of albendazole by 
pharmacies and by  cooperation of hospitals in endemic areas (hospi-  tals of the 
FrancEchino network). They also work in cooperation with the pathology laboratories. 
The STCS includes all solid organ transplant recipients in Switzerland since 2008, 
which represents more than 5000 patients at the end of 2018. The database includes 
clinical information and biological samples that are prospectively collected at 
baseline, 6 months and every year by transplant physicians in all 6 transplant centers 
of Switzerland [46]. This follow-up of patients has been made mandatory by law since 
2007. Collected information notably include all infectious disease episodes 
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occurring post-transplantation. 
 
Statistical analysis 
We intended to compare the data for the SOT recipients population to the data for the 
general population. However, statistical analysis would not be significant with such 
a small number of patients. This is therefore a descriptive study of a small  case series. 
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Results 
 
Patients population 
A total of 7 patients were identified: two in Switzerland and five in France. Five of 
them were kidney transplant recipients, two of which had to be transplanted a second 
time (for causes unrelated to AE). The other two patients were lungs and heart 
transplant recipients, respectively. The calculated incidence in the STCS cohort was 
5 cases per 100’000 patient-year, while it was not possible to calculate the incidence 
in the FrancEchino network. Median age at diagnosis was 57 years old (range 46-66). 
There were 5 women and 2 men in this population of patients. Immunosuppressive 
treatment was documented for 5 patients, with exact doses available in four of them 
(Table 2). 
 
Clinical presentation 
AE was a fortuitous radiologic discovery in otherwise asymptomatic patients in 5 
cases and presented with abdominal pain for the other two patients. The primary 
lesion was hepatic in 6 cases and pulmonary in one case. In this latter case, patient 
suffered of hepatorenal polycystic disease, making it difficult to assess the presence 
of hepatic AE. In the two  symptomatic cases, AE had extended into the pancreas   in 
one case and in the stomach and diaphragm in another case. The lesions were 
otherwise localized in the liver. The two patients with a N > 0 staging were both 
symptomatic at diagnosis. 
 
 
ID Prednisone MMF1 Cyclosporine Tacrolimus ∆t2 
1 5mg 1500mg - 1mg 43 
2 5mg - - 3mg 12 
3 ND ND ND ND ND 
4 ND ND ND ND 240 
5 7.5mg 2000mg 175mg - 117 
6 ? Unk. pos. - Unk. pos 57 
7 20mg 2000mg 150mg - 75 
1 
Mycophenolate mofetil 
2 
∆t is the interval in month between the transplantation and the diagnosis 
of AE 
Table 2: Immunosuppressive treatment (daily doses) 
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ID Transplant organ Primary lesion PNM stage Extension 
1 Lungs Liver P1N0M0 No 
2 Kidney1 Liver P1N1M1 Diaphragm and stomach 
3 Kidney Liver ND ND 
4 Kidney1 Liver P1N0M0 No 
5 Heart Liver P4N1M0 Head of pancreas 
6 Kidney Lungs PXN0M1 No 
7 Kidney Liver P1N0M0 No 
1 
Were transplanted twice (for reasons unrelated to AE) 
 
Table 3: Characterization of the lesions 
 
ID Western blot Em2+ Others 
1 Positive for E. multi. Negative Positive EgHF 
2 Positive (no details) - - 
3 Positive, band 7 & 26-281 Positive Positive EgHF 
4 Positive, band 7 & 26-281 - Positive IHA 
5 Positive, band 16 & 26-282 Negative Positive E. gran. ELISA 
6 Positive, band 7 & 26-281 - Positive IHA & E. gran. ELISA 
7 Positive, band 7 & 26-281 - Positive IHA 
1 
Those bands are shared by E. multilocularis and E. granulosus 
2 
Band 16 is more specific of E. multilocularis 
 
Table  4: Serologies 
 
Diagnosis 
Median time between the transplantation and the diagnosis is 66 months (range 12-
240). Imaging showed the absence of liver lesions in two patients, 26 and 43 months 
prior to diagnosis, respectively. For the latter patient, a serology performed 50 months 
prior to diagnosis was also negative. 
Diagnosis of AE was faster in the symptomatic cases than in the asymptomatic 
cases (0 vs 7.5 months, range [1 30], the duration being the interval between the initial 
radiologic finding and the diagnosis). The pulmonary lesion was mistaken for 
tuberculosis based on a wrongly interpreted biopsy and anti-tuberculosis treatment 
was initiated, with important interactions with the immunosuppressive drugs. The 
results of the serologies are summarized in Table 4. Western blots were positive in all 
cases, with detailed results available in 6 of them. They allowed a discrimination 
between E. multilocularis and E. granulosus in 2/6 cases (33%). The Em2+ serology 
was positive in only 1/3 case (33%). Crude antigen serologies (EgHF, IHA and E. 
granulosus ELISA) were always positive when tested. 
MRI were performed on all patients. In two cases, the imaging was atypical for 
AE : it had a pseudo-tumoral appearance in one and was similar to a metastasis in the 
other. Histopathological examinations were conducted in four cases. They were 
positive in two cases, inconclusive in one and led to the wrong diagnosis in one case 
(but ultimately hinted at the correct diagnosis after a second look). 
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Patient ID ∆t1 Imaging2 Serologies2 Outcome 
2 43 MRI (31 & 43): stable Unk. res.3 (19 & 42) Stabilization 
3 42 MRI (30 & 42): progression - Progression 
6 18 CT (6 & 12): stable Titers lowering3 (18) Stabilization 
7 48 MRI (18): stable - Stabilization 
  PET-CT (54): stable   
1 
Duration of the follow-up in months 
2 
With the timing of the examination in parentheses (in months) 
3 
Exact serology unknown 
 
Table  5:  Follow up 
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Figure 2: Evolution 
 
Treatment and outcome 
The outcome and treatment of the 7 patients of this case series are summarized in 
Figure 2. Four of the seven patients were operated on. However, complete resection 
was not possible in any of them.  Two  of those patients died of complications of  the 
operation. One additional patient died five months after the diagnosis. The  exact 
cause of the death is unknown. All surviving patients started a treatment of 
albendazole at 400mg bid, which was well tolerated. In particular, no significant liver 
function tests perturbation was reported and the doses of albendazole did not have to 
be changed for any of the patient. 
Information about the follow-up was available for four of the surviving patients 
and is summarized in table 5.  It included  MRIs,  serologies,  PET and  CT. AE  was 
stable for three patients and progressed in one patient. However, complete 
information on the follow-up was scarce, with a median follow-up duration of 42 
months. 
12  
− × 
 
 
 
 
 
 
Discussion 
 
This multicentric case series on AE in transplant patients is the largest to date. Despite 
low numbers, it somewhat concurs with previous studies and case reports about a 
potential increased incidence [32] and faster evolution of AE [32, 40] in SOT 
recipients. This study also highlights the diagnostic challenges, particularly regard- 
ing some cases of falsely positive and falsely negative imaging and serologies. Finally, 
we observed that albendazole seems to be well-tolerated and effective even in SOT 
recipients and that peri-operative mortality seems to be higher in this population, 
although the low number of cases does not allow to extract any firm conclusion. 
We estimated the incidence in Switzerland to about 5 new cases per 100000 
person-year in SOT recipients, while the incidence in the general population (in 
endemic areas) ranges between 0.03 and 0.27 new cases per 100000 person-year. 
Incidence in SOT recipients would thus be between 10     100    higher than that     of 
the general population, although these numbers are approximate and should be taken 
with caution given the low number of patients with AE in the STCS. 
The clinical presentation of AE in our series is different to that of the general 
population: while only 2/7 (28%) of SOT-recipients were symptomatic at diagnosis, 
75% experience symptoms in the general population. Discovery of AE was thus more 
often fortuitous in the SOT recipients population. A more common asymptomatic 
presentation in immunocompromised patients was also reported in another study [32], 
probably reflecting a closer follow-up of SOT recipients with more access to imaging 
techniques. The distribution of the PNM stages presents a more biphasic distribution 
than in general population [11],  with 3 patients with stage I AE and     3 with stage 
IV. About the same proportion of low PNM stages was also observed in the study by 
Chauchet et al [32] (41% vs 23% in the general population), and again, this is 
probably a consequence of an earlier (and fortuitous) detection of AE. The biphasic 
distribution is probably caused by the important immunosuppressive regimen 
administered to SOT recipients: it likely enhances the progression of AE, which 
develops more quickly from a low stage disease to a symptomatic and high- grade 
disease.  The short median interval  between transplantation and diagnosis  (66 months 
vs 84 for SOT recipients in [32]) and the proof of absence of AE for  two patients 26 
and 43 months prior to diagnosis bring further evidence of a faster evolution than the 
usual 10-15 years of latency. 
As already demonstrated in previous studies and case reports [32, 37, 39, 40], 
diagnosis of AE is more challenging in the setting of immunosuppression. In two case 
reports [37, 40], the diagnosis was made during surgery for a suspicion of hep- atic 
tumor. In patient 6 in our series, an initial misdiagnosis of tuberculosis was made 
after a biopsy was incorrectly interpreted, and anti-tuberculous drugs were 
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prescribed, with important interaction with immunosuppressive drugs. These cases 
illustrate the difficulty of diagnosing a rare disease with atypical presentation. In- 
cidental findings in asymptomatic patients and atypical imaging of AE probably 
account for the diagnostic delays (median of 7.5 months vs 11 in [32]) in immuno- 
compromised patients. Serologies are also affected by the immunosuppression. The 
usually effective Em2+ seems to lose sensitivity, while the Western-blot, usually 
specific and able to differentiate alveolar and hydatic echinococcosis, seems to lose 
its specificity. Specie-specific antigens, as used in the Em2+ serology, indeed seem 
to be less immunogenic than the antigens common for all the Echinococcus genus, 
losing some of their diagnostic value. We however reach the same conclusion as the 
study of Chauchet et al [32]: serologies using whole larval antigens or Echinococcus 
antigens are more reliable in this setting. In the context of hepatic lesion in SOT 
recipients with risk factors, AE should thus be included in the differential diagnosis 
and ruled-out, ideally by Western-blot. Interestingly, immunosuppression regimens 
that include Tacrolimus were linked to faster evolution of AE, although it is impos- 
sible to formally prove in such a small group of patients. With the importance of 
cellular immunity to stop or slow-down AE, it is expected that drugs inhibiting T 
lymphocytes would speed the disease. 
Regarding the therapeutic approach to AE, we observed two important issues. 
First, surgery was  complicated in SOT recipients,  with a peri-operative mortality  of 
50%. These figures can be due to particularly difficult surgeries in these two patients, 
but may also reflect the frail conditions of transplant recipients. In addi- tion, no 
complete resections could be obtained with those patients, despite the low PNM 
stages in the majority of them and despite available pre-operative imaging. Similar 
problems were observed in a cohort of liver transplant recipients due to AE [44]: 
surgeons noticed during the operation that not all parasitic tissue would be removable. 
Second, long-term use of albendazole seems to have been well supported, without any 
major interaction with the immunosuppressive drugs. Previous study had 
contradicting conclusions about albendazole tolerance: adverse effects were fre- 
quently reported in the immunosuppressed patients in the study by Chauchet [32]. 
Albendazole was however well tolerated after liver transplantation in the context of 
AE [43, 44]. Similarly to previous studies [32], albendazole was effective, allowing a 
stabilization of the disease in 75% of patients. 
A discontinuation of albendazole therapy has been proposed in selected immuno- 
competent patients, 2 years after radical surgery or in case of absence of parasite 
viability assessed by PET-CT and specific serology (Em2+) [24, 36]. The decision to 
stop albendazole is even more challenging in SOT recipients. Firstly, Em2+ appears 
to be less useful in this setting (loss of sensitivity due to the immunosuppression    in 
our series and in the study by Chauchet et al [32]). E. granulosus  IgG ELISA  has 
however been cited has a potential alternative to Em2 for the follow-up of SOT 
recipients [43]. Secondly, the performance of PET-CT for assessing the activity of 
AE has not been extensively evaluated in immunocompromised patients. Metabolic 
uptake around the parasitic lesion is thought to be mainly caused by cell mediated 
immunity and therefore, we may wonder whether the absence of uptake is due to  the 
efficacy of albendazole or to immunosuppression. 
Our study has several limitations. AE being a rare disease, we were able to 
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study a limited number of patients in the setting of solid-organ transplantation    and,  
therefore,  conclusions in our study should be taken with caution.  The lack   of a 
comprehensive transplant cohort (such as the STCS) in France prevented the 
evaluation of the whole incidence of AE in the 2008-2018 period for both countries. 
A collaborative registry of AE in SOT recipients grouping all endemic countries 
would be ideal, as it would reach a larger population pool than national registries 
Finally, we were not be able to obtain more epidemiological data on those patients, 
particularly about risk factors and compare them to those found in the general 
population. The biggest studies about AE were realized either retrospectively or 
thanks to registry like the FrancEchino. Unfortunately,  such registry doesn’t exist  at 
the European level. A collaborative registry grouping all endemic countries would be 
ideal, as it would reach a bigger population pool than national registries. 
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Conclusion 
 
This case series confirms previous findings about a higher incidence of AE in SOT 
recipients. Diagnosis is difficult with usual serologies unreliable, imaging sometimes 
atypical and asymptomatic patients concurring to cause a diagnosis delay. In the 
presence of hepatic lesions in SOT patient with risk factors (e.g. living in endemic 
area), it seems reasonable to search for AE with Western blot or indirect hemagglu- 
tination.  The high perioperative mortality and the difficulty to completely resect  the 
lesions in our cases suggest that a conservative treatment should be favored in SOT 
recipients. The efficacy of albendazole in this population and the absence of 
interactions with immunosuppressive drugs are further arguments in favor of this type 
therapeutic strategy. 
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